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Background: Hypercoagulability may be a key mechanism of
death in patients with coronavirus disease 2019 (COVID-19).
Objective: To evaluate the incidence of venous throm-
boembolism (VTE) and major bleeding in critically ill patients
with COVID-19 and examine the observational effect of early
therapeutic anticoagulation on survival.
Design: In a multicenter cohort study of 3239 critically ill
adults with COVID-19, the incidence of VTE and major
bleeding within 14 days after intensive care unit (ICU) admis-
sion was evaluated. A target trial emulation in which patients
were categorized according to receipt or no receipt of thera-
peutic anticoagulation in the first 2 days of ICU admission
was done to examine the observational effect of early thera-
peutic anticoagulation on survival. A Cox model with inverse
probability weighting to adjust for confounding was used.
Setting: 67 hospitals in the United States.
Participants: Adults with COVID-19 admitted to a partici-
pating ICU.
Measurements: Time to death, censored at hospital dis-
charge, or date of last follow-up.
Results: Among the 3239 patients included, the median
age was 61 years (interquartile range, 53 to 71 years), and
2088 (64.5%) were men. A total of 204 patients (6.3%) devel-
oped VTE, and 90 patients (2.8%) developed a major bleed-
ing event. Independent predictors of VTE were male sex and
higher D-dimer level on ICU admission. Among the 2809
patients included in the target trial emulation, 384 (11.9%)
received early therapeutic anticoagulation. In the primary
analysis, during a median follow-up of 27 days, patients who
received early therapeutic anticoagulation had a similar risk
for death as those who did not (hazard ratio, 1.12 [95% CI,
0.92 to 1.35]).
Limitation:Observational design.
Conclusion: Among critically ill adults with COVID-19, early
therapeutic anticoagulation did not affect survival in the tar-
get trial emulation.
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Hypercoagulability in patients with coronavirus disease2019 (COVID-19) may be a key mechanistic pathway
leading to multiorgan failure and death (1, 2). Patients
with COVID-19 have been reported to experience high
rates of venous thromboembolism (VTE) (3) and extracor-
poreal circuit thrombosis (4). Autopsies show extensive
fibrin thrombi within small vessels and capillaries (5).
These observations have prompted some experts to rec-
ommend empirical treatment with therapeutic anticoagu-
lation for critically ill patients with COVID-19 (1, 2).
Data on the incidence, risk factors, and prognosis
associated with VTE in patients with COVID-19 are largely
limited to single-center reports (4, 6–8). Granular, nation-
ally representative data on VTE, as well as major bleeding
events, are urgently needed. Furthermore, until data from
randomized trials on the effect of therapeutic anticoagula-
tion on outcomes in COVID-19 become available, clinical
care may be informed by robust estimates from observa-
tional data.
We used data from a multicenter cohort study of crit-
ically ill patients with COVID-19 admitted to intensive
care units (ICUs) in the United States to evaluate the inci-
dence of VTE and major bleeding, identify risk factors for
VTE, and examine the observational effect of early initia-
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METHODS
Study Design, Oversight, and Patient Population
We used data from STOP-COVID (Study of the
Treatment and Outcomes in Critically Ill Patients With
COVID-19), a multicenter cohort study that enrolled con-
secutive adults (aged ≥18 years) with laboratory-
confirmed COVID-19 admitted to participating ICUs at
67 geographically diverse hospitals in the United States
(Supplement Table 1 and Supplement Figure 1, avail-
able at Annals.org) (9). We included patients admitted to
ICUs between 4 March 2020 and 11 April 2020. We fol-
lowed patients until the first of hospital discharge, death,
or 8 May 2020. The study was approved with a waiver of
informed consent by the institutional review board at
each participating site.
Data Collection
Study personnel at each site collected data by manual
chart review and used a standardized case report form to
enter data into a secure online database. Patient-level
data included baseline information on demographics,
coexisting conditions, symptoms, medications before hos-
pital admission, and vital signs; daily data for the 14 days
after ICU admission on physiologic and laboratory values,
medications, nonmedication treatments, organ support,
and acute organ injury; and outcome data on vital status
at discharge. We also collected site-specific data on rou-
tine screening protocols for VTE and anticoagulation pro-
phylaxis. A complete list of variables is provided in the
Case Report Form in the Supplement, and definitions of
outcomes and events are listed in Supplement Table 2
(available at Annals.org). All data were validated through
a series of automated and manual verifications (Methods
section of the Supplement).
Definitions
We collected data on the incidence, clinical features,
and 28-day mortality in patients with radiographically
confirmed VTE (including deep venous thrombosis and
pulmonary embolism), ischemic stroke, andmajor bleed-
ing. Data on radiographically confirmed versus clinically
suspected VTE are reported separately. Ischemic stroke
was confirmed radiographically in all cases. We defined
major bleeding as occurring in a critical area or organ
(for example, intracranial, retroperitoneal, pericardial, or
intramuscular bleeding with compartment syndrome) or
requiring a procedural intervention; the requirement for
red blood cell transfusion alone was not sufficient to qual-
ify as a major bleed. This definition is similar to or stricter
than definitions used by landmark clinical trials of novel
anticoagulant reversal agents (10) and the International
Society for Thrombosis and Haemostasis (11). We also
collected data on the incidence of disseminated intravas-
cular coagulation, heparin-induced thrombocytopenia,
and coagulopathy (definitions provided in Supplement
Table 2).
Statistical Analysis
Continuous and categorical variables are expressed as
median (interquartile range [IQR]) and count (percentage),
respectively. We used multivariable logistic regression to
identify predictors of radiographically confirmed VTE. We
prespecified the following covariates, which were assessed
on the day of ICU admission: age; sex; body mass index;
current smoking status; active cancer; and leukocyte
count, platelet count, D-dimer, shock, invasive mechani-
cal ventilation, therapeutic anticoagulation, and aspirin
(Methods section of the Supplement). Missing data were
multiply imputed with 5 data sets, and results were
pooled using Rubin's rules (12).
To assess interhospital variation in VTE incidence
and use of therapeutic anticoagulation in the first 14
days after ICU admission, we employed multilevel logis-
tic regression modeling with patients nested in hospitals.
This approach addresses the poor reliability of estimates
stemming from hospitals submitting few cases. We addi-
tionally excluded hospitals that submitted data on fewer
than 30 patients (for VTE incidence) and fewer than 10
patients (for therapeutic anticoagulation) to further
improve the reliability of our estimates. We adjusted for
the same covariates as the aforementioned VTEmodel.
Target Trial Specification
To examine the observational effect of early initiation
of therapeutic anticoagulation on in-hospital survival, we
emulated a hypothetical target trial comparing patients
who received therapeutic anticoagulation in the 2 days
after ICU admission to those who did not. We used the
target trial framework to make our research question
explicit and to guide the design of the observational
analysis (13–16). The time period of 2 days was chosen
for treatment assignment to provide greater homogene-
ity between patients, to limit indication bias, to allow lon-
ger follow-up, and for biological plausibility, because
therapies initiated early and before irreversible organ
injury may be more likely to be beneficial (17). To emu-
late the eligibility criteria of a hypothetical clinical trial of
therapeutic anticoagulation, we excluded patients if they
were receiving anticoagulation before hospitalization or
if they had any of the following within 2 days after ICU
admission: confirmed or suspected VTE, extracorporeal
membrane oxygenation, major bleeding, or a platelet
count less than 50109 cells/L.
Target Trial Emulation
The primary analysis compares survival among patients
who received or did not receive therapeutic anticoagula-
tion in the first 2 days of ICU admission. Survival time was
defined as the interval from ICU admission to death, cen-
sored at hospital discharge, or the end of follow-up, which-
ever occurred first. Hazard ratios and 95% CIs were
estimated using a Cox model. Patients who initiated thera-
peutic anticoagulation on day 3 or later after ICU admission
were categorized in the control group, in keeping with an
intention-to-treat approach.
Inverse ProbabilityWeighting
We adjusted for confounding using inverse probabil-
ity weighting. We fit a logistic regression model with ini-
tiation of therapeutic anticoagulation in the first 2 days
of ICU admission as the outcome, conditional on the fol-
lowing covariates that were prespecified based on
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clinical judgment: age; sex; race; ethnicity; body mass
index; hypertension; diabetes mellitus; atrial fibrillation
or atrial flutter; coronary artery disease; congestive heart
failure; current smoking status; active cancer; duration of
symptoms before ICU admission; severity-of-illness cova-
riates assessed on ICU admission, including PaO2:FIO2,
shock, the renal, liver, and coagulation components of
the Sequential Organ Failure Assessment score (18), and
inflammation (assessed by C-reactive protein, D-dimer,
and ferritin); and concurrent therapies received on ICU
admission, including aspirin, neuromuscular blockade,
and prone positioning. Additional details are provided in












Median age (IQR), y 61 (53–71) 60 (50–67) 62 (52–71) 63 (55–74) 62 (51–71)
Male, n (%) 2088 (64.5) 149 (73.0) 1939 (63.9) 64 (71.1) 2024 (64.3)
Race, n (%)
White 1194 (36.9) 66 (32.4) 1128 (37.2) 33 (36.7) 1161 (26.9)
Black 1015 (31.3) 86 (42.2) 929 (30.6) 28 (31.1) 987 (31.3)
Asian 198 (6.1) 5 (2.5) 193 (6.4) 8 (8.9) 190 (6.0)
Other 832 (25.7) 47 (23.0) 785 (25.9) 21 (23.3) 811 (25.8)
Hispanic, n (%) 663 (20.5) 37 (18.1) 626 (20.6) 14 (15.6) 649 (20.6)
Median body mass index (IQR), kg/m2 30.3 (25.5–36.0) 30.9 (26.9–36.7) 30.3 (26.5–35.9) 28.4 (25.2–32.2) 30.4 (26.6–36.2)
Pregnant, n (%) 20 (0.6) 1 (0.5) 19 (0.6) 1 (1.1) 19 (0.6)
Coexisting conditions, n (%)†
Diabetes mellitus, insulin dependent 464 (14.3) 19 (9.3) 445 (14.7) 19 (21.1) 445 (14.1)
Diabetes mellitus, noninsulin dependent 847 (26.2) 53 (26.0) 794 (26.2) 30 (33.3) 817 (26.0)
Hypertension 1977 (61.0) 109 (53.4) 1868 (61.6) 60 (66.7) 1917 (60.9)
Chronic lung disease
COPD 273 (8.4) 15 (7.4) 258 (8.5) 8 (8.9) 265 (8.4)
Asthma 344 (10.6) 22 (10.8) 322 (10.6) 6 (6.7) 338 (10.7)
Other pulmonary disease 238 (7.4) 16 (7.8) 222 (7.3) 8 (8.9) 230 (7.3)
Current or former smoker 957 (29.6) 62 (30.4) 895 (29.5) 24 (26.7) 933 (29.6)
Coronary artery disease 431 (13.3) 23 (11.3) 408 (13.4) 19 (21.1) 412 (13.1)
Congestive heart failure 305 (9.4) 13 (6.4) 292 (9.6) 12 (13.3) 293 (9.3)
Chronic liver disease 107 (3.3) 3 (1.5) 104 (3.4) 4 (4.4) 103 (3.3)
Chronic kidney disease 407 (12.6) 21 (10.3) 386 (12.7) 15 (16.7) 392 (12.5)
End-stage kidney disease 98 (3.0) 4 (2.0) 94 (3.1) 9 (10.0) 89 (2.8)
Active cancer 162 (5.0) 9 (4.4) 153 (5.0) 6 (6.7) 156 (5.0)
Immunodeficiency 78 (2.4) 5 (2.5) 73 (2.4) 5 (5.6) 73 (2.3)
HIV/AIDS 48 (1.5) 5 (2.5) 43 (1.4) 0 (0.0) 48 (1.5)
Home medications affecting hemostasis,
n (%)
NSAIDs 267 (8.2) 22 (10.8) 245 (8.1) 3 (3.3) 264 (8.4)
Aspirin 715 (22.1) 41 (21.1) 674 (22.2) 34 (37.8) 681 (21.6)
Oral or parenteral anticoagulation 305 (9.4) 7 (3.4) 298 (9.8) 16 (17.8) 289 (9.2)
Median laboratory findings on the day of
ICU admission (IQR)
Leukocyte count,  109/L 8.2 (5.9–11.5) 8.6 (6.5–11.6) 8.16 (5.9 –11.5) 8.55 (5.9–13.2) 8.2 (5.9–11.5)
Hemoglobin, g/L 127 (111–141) 128 (113–143) 127 (111–141) 120 (87–133) 127 (112–141)
Platelet count,  109/L 213 (163–271) 218 (171–277) 212 (162–270) 177 (133–277) 213 (164–270)
D-dimer, mg/L 1.32 (0.70–3.26) 2.32 (1.01–9.22) 1.29 (0.69–3.05) 3.70 (1.35–15.41) 1.30 (0.70–3.18)
C-reactive protein, mg/L 157 (90–238) 171 (103–250) 157 (89–237) 129 (69–229) 158 (91–238)
Interleukin-6, IU/mL 6.2 (2.1–17) 3.5 (0.86–9.4) 6.6 (2.3–17.1) 3.4 (1.3–5.8) 6.5 (2.1–17.4)
Procalcitonin, mg/L 0.41 (0.15–1.38) 0.40 (0.18–1.40) 0.41 (0.15–1.37) 0.80 (0.30–3.96) 0.40 (0.15–1.34)
Ferritin, mg/L 1032 (505–2000) 1258 (651–2335) 1013.5 (499–2000) 1457.4 (714–3008) 1019 (501–2000)
Fibrinogen, g/L 6.14 (4.97–7.53) 6.31 (4.16–6.92) 6.12 (4.97–7.53) 3.96 (2.85–4.87) 6.17 (5.09–7.55)
Severity-of-illness on the day of ICU
admission, n (%)
Invasive mechanical ventilation 2132 (65.8) 144 (70.6) 1987 (65.5) 68 (75.6) 2062 (63.7)
Vasopressors 1364 (42.1) 98 (48.0) 1266 (41.7) 40 (44.4) 1008 (32.0)
Renal replacement therapy 118 (3.6) 8 (3.9) 110 (3.6) 6 (6.7) 112 (3.6)
COPD = chronic obstructive pulmonary disease; FEU = fibrinogen equivalent units; IQR = interquartile range; NSAID = nonsteroidal anti-
inflammatory drug; VTE = venous thromboembolism.
* The following data were missing: body mass index, 228 patients (7.0%); leukocyte count, 180 patients (5.6%); hemoglobin, 186 patients (5.7%);
platelet count, 195 patients (6.0%); D-dimer, 1615 patients (49.9%), C-reactive protein, 1291 patients (39.9%); interleukin-6, 2595 patients (80.1%);
procalcitonin, 1193 patients (36.7%); ferritin, 1423 patients (43.9%); and fibrinogen, 2648 patients (81.8%). All other variables had no missing data.
† The definitions of the coexisting conditions are provided in the Supplement.
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the Methods section of the Supplement. We used the
model's predicted probabilities to calculate stabilized
inverse probability weights (19), which were then used to
weight each individual's contribution to the survival curves
and to the Cox model. We used a robust (sandwich) var-
iance estimator to account for potential replications of
patients induced by inverse probability weighting, which
results in conservative 95%CIs.
Sensitivity Analyses
We conducted 5 sensitivity analyses of the target trial
emulation. First, we included the aforementioned covari-
ates in an unweighted Cox model. Second, to eliminate
the potential for immortal time bias (20, 21), we catego-
rized eligible patients into either the early therapeutic
anticoagulation group or the no early therapeutic antico-
agulation group on ICU day 1, and we repeated the
Table 2. Thrombosis, Bleeding, and Coagulation Abnormalities
Event* Patients, n (%) 28-Day Mortality: Deaths/Events, n (%)
Confirmed VTE 204 (6.3) 78/204 (38.2)
DVT (confirmed VTE events) 176 (86.3) 70/176 (39.8)
Lower-extremity DVT† 136 (66.6) 61/136 (44.9)
Proximal 63 (30.9) 24/63 (38.1)
Distal 47 (23.0) 25/47 (53.2)
Both proximal and distal 26 (12.8) 12/26 (46.2)
Upper-extremity DVT 49 (24.0) 15/49 (30.1)
Other DVT 5 (2.5) 2/5 (40.0)
PE (confirmed VTE events) 32 (15.7) 8/32 (25.0)
Proximal (lobar or segmental) 14 (6.7) 2/14 (14.3)
Distal (subsegmental) 7 (3.4) 0/7 (0.0)
Both proximal and distal 7 (3.4) 2/7 (28.6)
Diagnosed on V/Q scan (location not ascertained) 4 (2.0) 4/4 (100.0)
Suspected VTE events‡ 63 (2.0) 31/63 (49.2)
DVT 26 (41.3) 12/26 (46.2)
PE 42 (66.6) 24/42 (57.1)
Confirmed ischemic stroke 20 (0.6) 11/20 (55.0)
Major bleeding events§ 90 (2.8) 56/90 (62.2)
Site||
Bronchopulmonary 12 (13.3) 7/12 (58.3)
Body cavity (pleural, pericardial, peritoneal, retroperitoneal) 10 (11.1) 3/10 (30.0)
Central nervous system 13 (14.4) 8/13 (61.5)
Gastrointestinal 9 (32.2) 21/29 (72.4)
Genitourinary 3 (3.3) 2/3 (66.7)
Invasive sites 2 (2.2) 1/2 (50.0)
Mucocutaneous 2 (2.2) 1/2 (50.0)
Musculoskeletal and soft tissue 6 (6.7) 4/6 (66.7)
Site not specified or unknown 17 (18.9) 14/17 (82.4)
Required invasive hemostatic intervention 19 (21.1) 12/19 (63.2)
Received red blood cell transfusion for bleeding ¶ 53 (58.9) 31/53 (58.4)
Thrombocytopenia (platelet count <150  109/L) at time of bleed 32 (35.6) 27/35 (77.1)
Platelet count <50  109/L 6 (6.7) 6/6 (100.0)
Platelet count 50 to 99  109/L 13 (14.4) 11/13 (84.6)
Platelet count 100 to 149  109/L 16 (17.8) 10/16 (62.5)
Therapeutic anticoagulation at time of bleed 60 (66.7) 43/60 (71.7)
Antiplatelet therapy at time of bleed 24 (26.7) 15/24 (62.5)
Aspirin 24 (26.7) 15/24 (62.5)
P2Y12 antagonist (clopidogrel or ticagrelor) 5 (5.6) 4/5 (80.0)
Fatal bleed 25 (27.8) 25/25 (100.0)
Coagulopathy** 67 (2.1) 47/67 (70.1)
Disseminated intravascular coagulation†† 48 (1.5) 32/48 (66.7)
Heparin-induced thrombocytopenia 18 (0.6) 10/18 (55.6)
DVT = deep venous thrombosis; IQR = interquartile range; PE = pulmonary embolism; V/Q = ventilation/perfusion; VTE = venous
thromboembolism.
* Of the 90 patients with a major bleeding event, data regarding the platelet count at the event were missing for 6 patients (6.7%). All other data
were complete.
† 10 patients with lower-extremity DVT also had upper-extremity DVT, and 4 also had DVT in other (nonlimb) locations; these patients are included
in both totals.
‡ 4 patients with confirmed DVT had a suspected PE, and 1 patient had both a suspected DVT and PE; these patients are included in both totals.
§ Median values for coagulation variables at the time of the major bleeding event were as follows: platelet count, 167  109/L (IQR, 112 to 237);
prothrombin time, 15.1 seconds (IQR, 13.4 to 17.6); international normalized ratio, 1.3 (IQR, 1.1 to 1.5); and activated partial thromboplastin time,
39.9 seconds (IQR, 31.6 to 66.0).
|| 5 patients had major bleeding events from 2 distinct sites.
¶ Patients received a median of 2 units (range, 0 to 10 units) of packed red blood cells in the 48 h after the major bleeding event.
** Defined as a peak international normalized ratio >2.0 or a peak activated partial thromboplastin time >58 seconds in the absence of oral anticoa-
gulation or parenteral therapeutic anticoagulation.
†† As diagnosed by the treating physician.
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process for eligible patients on ICU day 2. Our final esti-
mates were obtained by pooling the data from the
nested target trials on ICU days 1 and 2, using inverse
probability weighting as previously described and in the
Methods section of the Supplement. Third, we repeated
the primary target trial but extended the exposure pe-
riod for initiation of therapeutic anticoagulation from the
first 2 days to the first 3 days after ICU admission. Fourth,
we stratified the Cox model by site. Fifth, rather than cen-
soring patients at hospital discharge, we kept them in
the risk set until 8 May 2020, the date of last follow-up.
Subgroup Analyses
We used similar methods as the aforementioned pri-
mary analysis to examine the observational effect of early
therapeutic anticoagulation on survival across the follow-
ing prespecified subgroups: age (≤60 vs. >60 years);
sex; body mass index (<40 vs. ≥40 kg/m2); days from
symptom onset to ICU admission (≤3 vs. >3); receipt of
invasive mechanical ventilation, shock, and PaO2:FIO2 ra-
tio (<100, 100 to 199, and ≥200 or not mechanically ven-
tilated) on ICU day 1; D-dimer level on ICU days 1 or 2
(≤1000, 1001 to 2500, and >2500 ng/mL); and number
of ICU beds before COVID-19 (<50, 50 to 99, and ≥100).
Analyses were done using SAS, version 9.4 (SAS
Institute), and Stata 14.2 (StataCorp).
Role of the Funding Source
This study was not funded.
RESULTS
Patient Characteristics
A total of 3239 patients from 67 sites were included
in this analysis. The median age was 61 years (IQR, 53 to
71), 2088 (64%) were men, and 2132 (65.8%) received
mechanical ventilation on ICU day 1. Additional charac-
teristics overall and according to the presence or ab-
sence of VTE and major bleeding are shown in Table 1
and Supplement Table 3 (available at Annals.org).
Overall, 1273 patients (39.3%) died, 1404 (43.4%) were
discharged from the hospital within 28 days, and 562
(17.4%) remained hospitalized at 28 days.
VTE,Major Bleeding, and Coagulation-
Associated Complications
Routine screening for VTE in critically ill patients with
COVID-19 occurred in 3 of the 67 hospitals (4.5%). A
total of 204 patients (6.3%) had radiographically con-
firmed VTE during the first 14 days of ICU admission
(Supplement Figure 2, panel A, available at Annals.org),
including 176 patients (5.4%) with deep venous throm-
bosis and 32 patients (1.0%) with pulmonary embolism
(Table 2). The 14-day radiographically confirmed VTE
rate in hospitals using universal lower-extremity Doppler
ultrasonography screening was 8.7%. The risk- and reli-
ability-adjusted incidence of radiographically confirmed
VTE across hospitals is shown in Supplement Figure 3,
panel A (available at Annals.org), with a median inci-
dence of 5.2% and a range of 1.1% at the lowest-
incidence hospital to 17.7% at the highest. An additional
63 patients (2.0%) had a clinically suspected VTE event.
A total of 20 patients (0.6%) had a radiographically
confirmed ischemic stroke. Among patients with radio-
graphically confirmed VTE or stroke, the 28-day mortality
was 38.2% and 55%, respectively.
Major bleeding occurred in 90 patients (2.8%) (Supple-
ment Figure 2, panel B), 56 of whom (62.2%) died within 28
days. The most common sites of bleeding were gastrointes-
tinal (32.2%) and intracranial (14.4%). A total of 60 of the 90
patients (66.7%) with a major bleeding event were receiving
therapeutic anticoagulation at the time of the event (Table
2). Other coagulation-associated complications included
coagulopathy (2.1%), disseminated intravascular coagulation
(1.5%), and heparin-induced thrombocytopenia (0.6%).
Predictors of VTE
In multivariable analysis, covariates associated with
radiographically confirmed VTE were male sex (odds ra-
tio [OR], 1.60 [CI, 1.13 to 2.27]) and higher D-dimer con-
centration on ICU day 1 (OR, 1.79 [CI, 1.14 to 2.81], for
D-dimer of 1001 to 2500 vs. ≤1000 ng/mL; OR, 2.50 [CI,
1.40 to 4.50], for 2501 to 10000 vs. ≤1000 ng/mL; and
OR, 4.20 [CI, 2.17 to 8.14], for >10000 vs. ≤1000 ng/mL).
Other covariates examined were not associated with VTE
(Supplement Figure 2, panel D). The increased risk for
VTE in men was observed across multiple categories of
body mass index and D-dimer (Supplement Figure 4,
available at Annals.org).
Interhospital Variation in Use of Anticoagulation
All participating centers reported routinely adminis-
tering, at a minimum, standard prophylactic doses of
Figure 1. Flow diagram for target trial emulation of therapeutic
anticoagulation.
Critically ill patients with laboratory-
confirmed COVID-19 admitted to
ICUs from 4 March 2020 to
11 April 2020 (n = 3239)
Excluded (n = 430)
   Received therapeutic anticoagulation
      before hospitalization: 305
   Received anticoagulation for a
      radiographically confirmed (n = 44) or
      clinically suspected (n = 13) DVT or
      PE within 2 d after ICU admission: 57
   Required anticoagulation for ECMO
      within 2 d after ICU admission: 28
   Had major bleeding episode within 2 d
      after ICU admission: 14
   Had a platelet count <50 × 109 cells/L
      within 2 d after ICU admission: 26
Included (n = 2809)
Initiated therapeutic anticoagulation
within 2 d after ICU admission
(n = 384)
   On ICU day 1: 231 (60.2%)
   On ICU day 2: 153 (39.8%)
Did not initiate therapeutic
anticoagulation within 2 d
after ICU admission
(n = 2425)
COVID-19= coronavirus disease 2019; DVT= deep venous thrombosis;
ECMO= extracorporeal membrane oxygenation; ICU= intensive care
unit; PE= pulmonary embolism.
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Median age (IQR), y 62.0 (52.0–71.0) 62.0 (51.0–71.0) 62 (52–72) 62 (51–71)
Age group, n (%)
18–39 y 35 (9.1) 222 (9.2) (8.2) (9.1)
40–59 y 139 (36.2) 855 (35.3) (36.0) (35.4)
60–79 y 182 (47.4) 1146 (47.3) (47.9) (47.3)
≥80 y 28 (7.3) 202 (8.3) (7.9) (8.2)
Male, n (%) 264 (68.8) 1549 (63.9) (63.9) (64.5)
White race, n (%) 138 (35.9) 860 (35.5) (32.4) (35.5)
Non-Hispanic ethnicity, n (%) 235 (61.2) 1620 (66.8) (66.2) (66.1)
Median body mass index (IQR), kg/m2 29.8 (26.1–35.9) 30.3 (26.4–35.9) 31.1 (26.7–35.9) 30.3 (26.4–35.9)
Body mass index, n (%)
<30 kg/m2 183 (47.7) 1112 (45.9) (44.0) (46.1)
30–39.9 kg/m2 128 (33.3) 861 (35.5) (37.6) (35.3)
≥40 kg/m2 52 (13.5) 341 (14.1) (13.7) (14.0)
Coexisting disorders, n (%)
Hypertension 235 (61.2) 1438 (59.3) (57.5) (59.5)
Diabetes mellitus 144 (37.5) 973 (40.1) (36.1) (39.7)
Coronary artery disease 41 (10.7) 290 (12.0) (11.5) (11.8)
Atrial fibrillation/flutter 14 (3.6) 59 (2.4) (3.0) (2.6)
Congestive heart failure 20 (5.2) 173 (7.1) (6.3) (6.9)
Current smoker 13 (3.4) 128 (5.3) (4.4) (5.0)
Active cancer 16 (4.2) 105 (4.3) (4.1) (4.3)
Severity of illness on ICU admission, n (%)
Days from symptom onset to ICU admission
0–3 71 (18.5) 463 (19.1) (21.0) (19.1)
>3 313 (81.5) 1962 (80.9) (79.0) (80.9)
Mechanical ventilation and hypoxemia
Not mechanically ventilated 80 (20.8) 898 (37.0) (33.9) (34.8)
Mechanically ventilated and PaO2:FIO2 ≥200 55 (14.3) 297 (12.2) (11.4) (12.5)
Mechanically ventilated and PaO2:FIO2 <200 204 (53.1) 983 (40.5) (42.3) (42.2)
Shock† 62 (16.1) 200 (8.2) (8.9) (9.3)
Renal SOFA score‡
0 (Cr <106.1 mmol/L [1.2 mg/dL]) 196 (51.0) 1534 (63.3) (64.8) (61.7)
1 (Cr 106.1–168 mmol/L [1.2–1.9 mg/dL]) 88 (22.9) 517 (21.3) (20.0) (21.5)
2–4 (Cr > 176.8 mmol/L [2 mg/dL], UOP <500 mL, RRT)§ 100 (26.0) 374 (15.4) (15.2) (16.8)
Liver SOFA score‡
0 (bilirubin <20.5 mmol/L [<1.2 mg/dL]) 334 (87.0) 2245 (92.6) (92.2) (91.9)
1 (bilirubin 20.5–34.1 mmol/L [1.2–1.9 mg/dL]) 43 (11.2) 137 (5.6) (6.3) (6.3)
2–4 (bilirubin ≥34.2 mmol/L [≥2 mg/dL]) 7 (1.8) 43 (1.8) (1.5) (1.8)
Coagulation SOFA score‡
0 (platelet count ≥150  109/L) 328 (85.4) 2010 (82.9) (85.2) (83.2)
1 (platelet count 100–149  109/L) 43 (11.2) 333 (13.7) (12.4) (13.4)
2 (platelet count <100  109/L) 13 (3.4) 82 (3.4) (2.4) (3.4)
Inflammation||
Inflamed 331 (86.2) 1765 (72.8) (74.6) (74.6)
Not inflamed 28 (7.3) 254 (10.5) (10.9) (10.0)
Therapies administered on ICU admission, n (%)
Aspirin 70 (18.2) 349 (14.4) (13.9) (14.9)
Neuromuscular blockade 120 (31.3) 500 (20.6) (23.0) (22.1)
Prone positioning 92 (24.0) 499 (20.6) (21.8) (21.0)
Cr = creatinine; ICU = intensive care unit; IPW = inverse probability of treatment weighting; RRT = renal replacement therapy; SOFA = Sequential
Organ Failure Assessment; UOP = urine output.
* A total of 1.4% of covariate data were missing in this analysis, as follows: body mass index, 132 of 2809 patients (4.7%); inflammation, 431 of 2809
patients (15.3%); Pao2:FIo2, 292 of 1831 patients who were mechanically ventilated (15.9%). All other data were complete.
† Shock was defined as the requirement for ≥2 vasopressors.
‡ Categories 2, 3, and 4 of the renal, liver, and coagulation components of the SOFA score were binned due to low frequency.
§ Includes both acute RRT as well as end-stage kidney disease requiring RRT.
|| Inflamed was defined as ≥1 of the following on either ICU days 1 or 2: C-reactive protein >100 mg/L, D-dimer >1.00 mg/L, or ferritin >10 g/L.
Noninflamed was defined as ≥1 value that was below the threshold on either ICU day 1 or 2 and no value that was above the threshold. Unknown
was defined as all 3 values being missing on both ICU days 1 and 2.
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anticoagulation (enoxaparin, 40 mg subcutaneously once
daily, or equivalent, or unfractionated heparin, 5000 units
subcutaneously 2 to 3 times daily, with or without weight-
based dose adjustment) for all critically ill patients with
COVID-19. Eight centers (12%) transitioned to higher-
than-standard doses for some or all patients with COVID-
19 during the study period, using either a risk-adapted
approach (based on such criteria as D-dimer) or empirical
dose escalation (that is, enoxaparin, 30 to 40 mg twice
daily, or equivalent) for all patients.
A total of 1412 patients (43.6%) received therapeutic
anticoagulation within 14 days after ICU admission (Supple-
ment Figure 2, panel C). The median time to initiation was 3
days (IQR, 1 to 7), and the most common reasons were
concern for a hypercoagulable state (40.8%), atrial fibrilla-
tion or atrial flutter (18.8%), and suspected or confirmed
VTE (16.9%). Most patients received unfractionated heparin
(62.6%) or low-molecular-weight heparin (34.4%), with a mi-
nority receiving direct thrombin inhibitors and other agents
(Supplement Table 4, available at Annals.org). The risk- and
reliability-adjusted rate of therapeutic anticoagulation use var-
ied widely across hospitals, with a median rate of 39.8% and
a range of 15.1% to 78.5% at the lowest-use and highest-use
hospitals, respectively (Supplement Figure 3,panel B).
Target Trial Emulation
Among the 3239 patients enrolled, 2809 (86.7%)
were included in the target trial (Figure 1). A total of 384
patients (11.9%) were treated with early therapeutic anti-
coagulation. The characteristics of patients before and
after applying inverse probability of treatment weighting
are shown in Table 3, and indications for therapeutic
anticoagulation in the first 2 days of ICU admission in
patients included in the target trial emulation are listed in
Supplement Table 5 (available at Annals.org). Before
applying the weighting, patients treated with early thera-
peutic anticoagulation were more likely to have shock
and greater severity of hypoxemia and renal dysfunction
on ICU admission than were patients not treated with
early therapeutic anticoagulation. Other characteristics
were similar between groups (Table 3). After weighting
was applied, baseline and acute severity-of-illness char-
acteristics were well balanced between groups (Table 3
and Supplement Figure 5 [available at Annals.org]), with
standardized differences below 0.1 for all 22 covariates.
During a median follow-up of 27 days (IQR, 15 to
35), 1066 of the 2809 patients (38.0%) died, including
179 (46.6%) treated with early therapeutic anticoagula-
tion and 887 (36.6%) not treated with early therapeutic
anticoagulation. In the primary analysis, patients treated
with early therapeutic anticoagulation had a similar sur-
vival to those not treated with early therapeutic anticoa-
gulation (hazard ratio, 1.12 [CI, 0.92 to 1.35]) (Figures 2
and 3). Results were similar across all sensitivity and sub-
group analyses (Figure 3).
DISCUSSION
This multicenter cohort study of 3239 critically ill
adults with COVID-19 found that 6.3% of patients devel-
oped a radiographically confirmed VTE and 2.8% had a
major bleeding event in the 14 days after ICU admission.
Male sex and higher D-dimer levels at the time of ICU
admission were each independently associated with a
higher risk for VTE. Patients who received early therapeu-
tic anticoagulation had similar in-hospital survival com-
pared with those who did not. These data suggest that
rates of VTE in critically ill patients with COVID-19 may
be considerably lower in the United States than in other
countries, and that initiation of early therapeutic anticoa-
gulation may not have a survival benefit.
Single-center and regional studies, primarily from
Europe, reported VTE rates ranging from 5% to 42% in
critically ill patients with COVID-19 (4, 6–8, 22, 23), and a
recent meta-analysis that included 1981 patients found a
rate of 23.9% (24). The 6.3% incidence of VTE that we
observed is similar to that reported by a study conducted
in 2 New York City hospitals, which found a 7.7% inci-
dence of VTE among patients who were mechanically
ventilated (25). Our findings are also consistent with prior
reports in critically ill patients without COVID-19 receiving
Figure 2. Target trial emulation.
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standard doses of heparin-based thromboprophylaxis
(26). Notably, standard doses of low-molecular-weight
heparin thromboprophylaxis used by some of the
European cohorts (for example, nadroparin, 2850 IU daily)
(4, 7) are lower than the standard prophylactic dose used
by most centers in this study. In addition, the high rate of
initiation of therapeutic anticoagulation in our cohort
(43.6% of all patients by day 14) may have contributed to
our lower rates of VTE. Of importance, our VTE risk
prediction model only included those with radiographi-
cally confirmed VTE (6.3%) and not those with suspected
VTE (2.0%), as many patients with suspected VTE may
have had alternative explanations for cardiopulmonary
decompensation, including worsening of COVID-19 lung
andmyocardial disease.
We identified 2 predictors of VTE in critically ill
patients with COVID-19: male sex and higher D-dimer
level on ICU day 1. Both of these factors have been
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associated with adverse outcomes in COVID-19 (27–30)
but have not been rigorously studied in the context of
VTE. Elevated D-dimer on ICU day 1 may be indicative of
elevated coagulation activation and therefore truly pre-
dictive of elevated VTE risk or may be representative of
an existing thrombus. It is tempting to speculate that
early, empirical therapeutic anticoagulation could be
beneficial in select patients, such as men with elevated
D-dimer on ICU admission. However, in our target trial
emulation, we found no benefit of early therapeutic anti-
coagulation overall or in any subgroup.
We also examined rates of major bleeding. Although
we found the rate to be approximately half as frequent
as VTE, the associated 28-day mortality was much higher
in patients with major bleeding (62.2% vs. 38.2%).
Furthermore, two thirds of the major bleeding events
occurred in patients receiving therapeutic anticoagula-
tion. The high mortality associated with major bleeding
in critically ill patients with COVID-19 highlights the need
to identify which patients, if any, may benefit from thera-
peutic anticoagulation in the absence of standard indica-
tions. This need is further underscored by the considerable
interhospital variation we detected in the use of therapeutic
anticoagulation, which may reflect the lack of available evi-
dence to guide decisionmaking.
We also sought to examine the observational effect
of early therapeutic anticoagulation on survival. When
data from randomized trials are unavailable, analyzing
observational data using a target trial emulation frame-
work may provide more robust estimates on which to
guide practice than traditional approaches (31–33).
Traditional observational studies that do not explicitly
emulate a target trial have resulted in erroneous findings,
such as the conclusion that postmenopausal hormone
therapy was associated with a 30% lower risk for coro-
nary heart disease (34). These findings become null
when the observational analysis is designed to explicitly
emulate the corresponding target trial (35), a practice
that helps minimize some of the biases that commonly
affect observational studies. Our target trial emulation
found that early initiation of therapeutic anticoagulation,
compared with prophylactic-dose anticoagulation, did
not affect survival. One potential explanation for our find-
ings is that therapeutic anticoagulation may have
reduced the risk for VTE but at the cost of an increased
risk for major bleeding. Alternatively, other pathways of
injury, such as inflammation (36), may bemore important
determinants of survival in critically ill patients with
COVID-19 and may not have been affected by anticoa-
gulation dose. Of note, our findings are consistent with
the recommendations endorsed by several professional
societies against broad empirical institution of therapeu-
tic anticoagulation in patients with COVID-19 (37, 38).
Our findings differ from those recently reported by a
single-center study that found an association between
therapeutic anticoagulation and decreased mortality in
patients with COVID-19 who are mechanically ventilated
(2). However, the latter study was limited by its inability
to account for immortal time bias or severity-of-illness dif-
ferences between groups. Furthermore, the reported
short-term mortality of 62.7% in the patients who did not
receive therapeutic anticoagulation is higher than in
many cohorts and suggests the potential for residual
confounding.
Our study has several strengths. We used granular
data from many consecutive critically ill patients with
laboratory-confirmed COVID-19, thereby minimizing
selection or surveillance bias at each center. We included
patients from 67 geographically diverse sites throughout
the United States, thereby increasing the generalizability
of our findings and allowing us to examine interhospital
variation in the use of therapeutic anticoagulation.
Furthermore, all data were obtained by detailed chart
review rather than reliance on administrative or billing
codes, which have well-described limitations in general
(31–33, 39) and in the context of VTE (40). Very few data
were missing for the covariates in our target trial emula-
tion, which was the primary analysis in this study. Our tar-
get trial emulation included robust methods to account
for immortal time bias and confounding by indication.
Finally, results were similar across multiple sensitivity and
subgroup analyses.
Our study has several limitations. First, as with all
observational analyses, we cannot exclude the possibility
of residual confounding. Second, we only captured data
on VTE andmajor bleeding events for the first 14 days af-
ter ICU admission and thus likely underestimated their
true incidence in this population. Third, VTE events (and
pulmonary emboli, in particular) were likely underdiag-
nosed given the logistic challenges of imaging in crit-
ically ill patients with COVID-19 (41). Nevertheless, the
considerably lower incidence of VTE in our study than in
prior studies raises questions about the appropriateness
of institutional policies advocating universal dose escala-
tion of prophylactic anticoagulation in critically ill patients
with COVID-19.
Using data from a nationally representative multicen-
ter cohort study of critically ill adults with COVID-19 in
the United States, we found the rates of radiographically
confirmed VTE andmajor bleeding to be 6.3% and 2.8%,
respectively. Male sex and higher D-dimer levels were in-
dependently associated with VTE. Patients who received
therapeutic anticoagulation in the first 2 days of ICU
admission had similar in-hospital survival compared with
those who did not. Our findings do not support early em-
pirical use of therapeutic anticoagulation in critically ill
patients with COVID-19. These findings highlight the
need for well-designed, adequately powered random-
ized clinical trials of therapeutic anticoagulation in crit-
ically ill patients with COVID-19.
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